Safety and Effectiveness of Antegrade Flexible Ureteroscopy-Assisted Percutaneous Nephrolithotomy for Staghorn Calculi

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorTianjin Medical University Second Hospital

About this trial

Objective This study aims to evaluate the safety and efficacy of antegrade flexible ureteroscopy-assisted PCNL for the treatment of staghorn calculi, compared with standard PCNL.

Methods This prospective, multicenter, randomized controlled trial plans to enroll 420 patients with staghorn calculi, randomly assigned into two groups: the experimental group (antegrade flexible ureteroscopy-assisted PCNL, n=210) and the control group (standard PCNL, n=210). The primary endpoint is stone-free rate (defined as no residual fragment ≥2 mm on postoperative CT). Secondary endpoints include operative time, number of percutaneous tracts, rate of secondary procedures, hemoglobin decrease, postoperative complications (Clavien-Dindo classification), and length of hospital stay. All patients will undergo CT evaluation on postoperative day 2. Subgroup analysis will be performed according to the number of stone branches (≥5 vs \<5).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • antegrade flexible ureteroscopy-assisted PCNL

    Procedure/Surgery

    antegrade flexible ureteroscopy-assisted PCNL

  • single PCNL

    Procedure/Surgery

    single PCNL

Treatment groups

420 Participants
are divided into 2 treatment groups
Group A: antegrade flexible ureteroscopy-assisted PCNLExperimental treatment 1 intervention
Group B: single PCNLOther 1 intervention

Trial outcomes

Primary outcomes

1

Immediately stone-free rate (SFR)

defined as no residual fragment ≥2 mm on postoperative CT

Time frame
On postoperative day 2, a non-contrast CT of the urinary system will be performed, and the absence of residual fragments larger than 2 mm will be defined as stone-free.

Secondary outcomes

1

Operative time

Operative time

Time frame
From the establishment of the first percutaneous renal tract to the placement of the final nephrostomy tube.
2

Duration of hospital stay

Duration of hospital stay

Time frame
Up to 3 months.
3

Complications

Complications

Time frame
Up to 3 months.

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Tianjin Medical University Second Hospital

Lead sponsor

Chinese PLA General Hospital

Collaborator

Tianjin Medical University General Hospital

Collaborator

Peking University People's Hospital

Collaborator

First Hospital of China Medical University

Collaborator

The Second Affiliated Hospital of Dalian Medical University

Collaborator

The First Affiliated Hospital of Guangzhou Medical University

Collaborator

Second Affiliated Hospital of Guangzhou Medical University

Collaborator

The First Affiliated Hospital with Nanjing Medical University

Collaborator

Beijing Tsinghua Changgeng Hospital

Collaborator

The First Affiliated Hospital of Soochow University

Collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborator

The Affiliated Hospital of Qingdao University

Collaborator

Wuhan TongJi Hospital

Collaborator

This trial is not recruiting at the moment. You can still explore other options: